Our TBG nanocapsule containing siRNAs directed against either both CDK11 genes or against CK2α and CK2α′ provides protection to the nucleic acid during circulation and releases the siRNA within the cancer cells to downregulate the targeted gene expression. This evidence concerns the gene CDK19 and cancer.